Fresenius SE: Berenberg cuts target price, maintains 'buy'

(CercleFinance.com) - Berenberg has trimmed its target price for German healthcare conglomerate Fresenius to from 89.
1 euros 88.1 euros while maintaining a "buy" rating on the stock.

In a note sent to clients, the broker says that Fresenius' shares are being held back by three key concerns, i.e. the pending acquisition of Akorn, general concerns about the generics business and concerns about slowing growth in the German part of the hospital business.

In the report, Berenberg concludes that these factors create an "attractive entry point" to a "high-quality growth story," noting that its new target price still offers upside potential of 38%.

Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.